Document:

<PAGE>

                                                                   EXHIBIT 10.10

                      POINT OF CARE DATA SERVICES AGREEMENT

                                     BETWEEN

                                MERCK & CO., INC.

                                       AND

                          MEDCO HEALTH SOLUTIONS, INC.

<PAGE>

                      POINT OF CARE DATA SERVICES AGREEMENT

         THIS POINT OF CARE DATA SERVICES AGREEMENT (this "Agreement"), dated as
of June 28, 2002, is entered into between Merck & Co., Inc., a New Jersey
corporation ("Merck"), and Medco Health Solutions, Inc., a Delaware corporation
("Medco"). Merck and Medco are each referred to individually as a "Party," and
collectively as the "Parties".

                                    RECITALS

         A. Medco has partnered with a variety of third party technology vendors
to develop certain point-of-care ("POC") technologies and initiatives that allow
physicians to write prescriptions, receive formulary and prescription
information and communicate electronically with Medco through the use of
computers and wireless hand-held devices (the "POC Channels").

         B. Medco also provides to Merck periodic summary reports concerning the
use of the POC Channels, which Merck uses to better understand POC distribution
and capabilities, and for general marketing purposes.

         C. The Parties desire to continue to exchange information and expand
the exchange of information under the terms and conditions of this Agreement.
Accordingly, the Parties agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         For the purpose of this Agreement, the following capitalized terms
shall have the following meanings:

         1.1 Capture Rate. "Capture Rate" shall mean the percentage of
Participating Physician prescriptions captured on the POC Channel. Capture Rate
shall be equal to the number of Medco prescriptions written annually by
Participating Physicians through the POC Channels divided by the total number of
Medco prescriptions written annually by Participating Physicians

         1.2 Confidential Disclosure Agreement. "Confidential Disclosure
Agreement" shall mean that certain Confidential Disclosure Agreement to be
entered into between the Parties.

         1.3 Effective Date. "Effective Date" shall mean the date that this
Agreement is executed by the Parties.

         1.4 Final Separation. "Final Separation" means the date as of which
Merck divests itself of its equity interest in Medco, currently expected to be
by means of a distribution of Medco shares to Merck shareholders.

         1.5 Indemnification Agreement. "Indemnification Agreement" shall mean
that certain Indemnification and Insurance Matters Agreement to be entered into
between the Parties.

                                      -1-

<PAGE>

         1.6  Intellectual Property. "Intellectual Property" shall mean (a) all
inventions (whether patentable or unpatentable and whether or not reduced to
practice), all improvements thereon, and all patents, patent applications and
patent disclosures, together with all reissuances, continuations,
continuations-in-part, revisions, extensions and reexaminations thereof, (b) all
trademarks, service marks, trade dress, logos, trade names, domain names, and
corporate names, together with all translations, adaptations, derivations and
combinations thereof and including all goodwill associated therewith, and all
applications, registrations and renewals in connection therewith, (c) all
copyrights and all applications, registrations and renewals in connection
therewith, (d) all trade secrets and confidential business information
(including ideas, research and development, know-how, formulas, compositions,
manufacturing and production processes and techniques, methods, schematics,
technology, technical data, designs, drawings, flowcharts, block diagrams,
specifications, customer and supplier lists, pricing and cost information and
business and marketing plans and proposals), (e) all computer software
(including data and related documentation), (f) all other proprietary rights,
(g) all copies and tangible embodiments of the foregoing categories of
intellectual property listed in subsections (a) through (f) (in whatever form or
medium), and (h) all licenses, sublicenses, agreements, or permissions related
to the foregoing categories of intellectual property listed in subsections (a)
through (g).

         1.7  Participating Merck Identified Physicians. "Participating Merck
Identified Physicians" shall mean the particular physicians who are
Participating Physicians in Medco's POC initiative and who Merck from time to
time notifies Medco, in accordance with the specifications listed in Schedule
1.7, are recipients of Merck's marketing or market research activity.

         1.8  Participating Physicians. "Participating Physicians" shall mean
those physicians who subscribe to the POC Channels and who use such POC Channels
to support and enable prescription writing and who use the POC Channels to write
prescriptions at least twice a month.

         1.9  Person. "Person" shall mean any individual, corporation,
association, partnership (general or limited), joint venture, trust, estate,
limited liability company, or other legal entity or organization.

         1.10 POC Channels. "POC Channels" shall have the meaning specified in
Recital A.

         1.11 POC Deliverables. "POC Deliverables" shall mean the deliverables
to be provided to Merck under Section 2.3 of this Agreement and the applicable
Schedules.

         1.12 Subsidiary. "Subsidiary" of either Party shall mean a corporation
or other organization whether incorporated or unincorporated, of which at least
a majority of the securities or interests having by the terms thereof ordinary
voting power to elect at least a majority of the board of directors or others
performing similar functions with respect to such corporation or other
organization is directly or indirectly owned or controlled by such Party or by
any one or more of its Subsidiaries, or by such Party and one or more of its
Subsidiaries. For purposes of this Agreement, neither Medco nor any of its
Subsidiaries shall be deemed to be a Subsidiary of Merck.

         1.13 Term. "Term" shall have the meaning set forth in Section 5.1 of
this Agreement.

                                      -2-

<PAGE>

         1.14 Termination Date. "Termination Date" shall mean the date that the
Agreement is terminated pursuant to Article V.

                                   ARTICLE II

                           DELIVERABLES TO BE PROVIDED

         2.1  Merck Input Regarding POC Channel Content and POC Deliverables.
Merck shall have the right, at least once in each calendar quarter, to
participate with Medco in a joint POC planning meeting and to provide input on
the design, recommended clinical content and information tracked for the POC
Channels. The inclusion or use in the POC Channels of the material provided by
Merck shall be at the discretion of Medco. Merck shall have the right, within
reason, to request additional types of information be gathered from the POC
Channels and analyses be performed on data collected from or on the POC
Channels. Medco shall use its best efforts to accommodate Merck's suggestions
regarding these additional data and analyses, assuming they are not prohibited
by law, regulation, or third-party contractual limitation, and that they are not
operationally or methodologically impracticable. In the event that Medco
declines to follow such suggestions, Medco shall provide Merck with a good faith
reason for its decision.

         2.2  Control Over Content. Medco and/or the third party technology
vendors shall have final control over the content of the POC Channels. Medco
shall keep Merck apprised of all POC functionality that Medco technology
partners have developed and deployed.

         2.3  POC Deliverables. Medco shall provide to Merck the reports and
services listed in Schedule 2.3 concerning the POC Channels.

         2.4  Clarifying and Backup Data. Upon reasonable request by Merck,
Medco will use its best efforts to provide clarifications to and explanatory
data for the reports and statistics specified in Schedule Section 2.3, subject
to Medco's duty to safeguard patient information under Article IX of this
Agreement.

                                   ARTICLE III

                                  COMPENSATION

         3.1  Fees for POC Deliverables. During the Term, Merck shall pay Medco
fees on a semi-annual basis, in arrears, calculated in accordance with Schedule
3.1.

         3.2  Invoices. Medco shall provide Merck with semi-annual invoices, on
June 1 and December 1, reflecting the estimated fees payable for the semi-annual
period ending June 30 or December 31, as determined in accordance with Schedule
3.1. Actual fees payable shall be calculated promptly after the end of each
calendar year, and a final invoice for the year, reflecting a true-up of any
adjustments from the estimated fees previously billed, will be provided by Medco
to Merck by March 1.

                                      -3-

<PAGE>

                                   ARTICLE IV

                               GENERAL OBLIGATIONS

         4.1 Performance Parameters. To the extent that performance parameters
or specifications are established in this Agreement, Medco shall perform its
obligations in accordance with those parameters and specifications. To the
extent that specific performance parameters are not specifically enumerated in
this Agreement, Medco shall use reasonable commercial efforts to provide the POC
Deliverables.

                                   ARTICLE V

                              TERM AND TERMINATION

         5.1 Term. The Term of this Agreement shall commence on the Effective
Date and continue through and including December 31, 2005.

         5.2 Termination in Full. Merck may terminate this Agreement, for any
reason or no reason, effective January 1, 2003 or at any later date upon 90 days
prior written notice to Medco. In the event such termination occurs mid-year,
Medco shall furnish a final invoice to Merck within 60 days following the
effective date of termination. The final invoice shall be calculated in
accordance with Schedule 3.1, including a true-up against prior estimated
payments, except that the actual performance data shall be calculated as of the
effective date of termination, and the fees payable shall be pro rated for the
number of months from January 1 of the year of termination to the effective date
of termination.

         5.3 Termination in Part. Merck may also terminate this Agreement in
part, by eliminating its request for one or more of the POC Deliverables, for
any reason or no reason, effective January 1, 2003 or at any later time upon 90
days prior written notice to Medco. In the event that Merck terminates this
Agreement in part, both the base fee and the performance fee shall be reduced
proportionately by the proportionate value of the terminated POC Deliverable to
the fees for all the POC Deliverables, and the parties shall promptly seek to
agree upon that proportionate reduction.

         5.4 Effect of Termination. Termination of this Agreement shall relieve
and release the Parties from any further liabilities and obligations hereunder
with respect to the services terminated except any liabilities or obligations
that accrued prior to the effective date of such termination and except as
provided in Section 5.5.

         5.5 Survival. Articles VI, VIII and XI shall survive termination of
this Agreement.

                                      -4-

<PAGE>

                                   ARTICLE VI

                                 CONFIDENTIALITY

         6.1 The terms of the Confidential Disclosure Agreement shall apply to
any Confidential Information (as defined in Section 6.2) of either Party
provided to the other Party for the purpose of providing Services under this
Agreement.

         6.2 Confidential Information shall have the meaning set forth in
Section 1.2 of the Confidential Disclosure Agreement; without limiting that
definition, Confidential Information shall also specifically include: (a)
Merck's list of identified physicians, (b) information indicating the success in
reaching Merck Identified Physicians; (c) any information revealing what data
Merck sought to include in or obtain from the POC Channels; and (d) the data and
reports exchanged by the Parties under this Agreement.

         6.3 In addition to those obligations imposed by the Confidential
Disclosure Agreement, Confidential Information shall only be used by the Party
receiving it for the limited purposes under this Agreement for which that
Confidential Information is provided, and for no other purpose. Notwithstanding
this restriction, Merck may use the reports provided to it under this Agreement:

             (a)  internally, to better understand POC distribution and
                  capabilities, and for general marketing purposes, and

             (b)  may share those reports (other than the particular items of
                  data noted as exceptions on Schedule 2.3.2) externally with

                  (i)   its consultants, advisors, marketing partners, and
                        co-promotion partners,

                  (ii)  joint ventures in which Merck is a partner, and

                  (iii) vendors

                  other than any pharmacy benefit manager, any health care plan
                  that functions as a pharmacy benefit manager, or any entity
                  the offers hardware, software or content to physicians in the
                  POC market, in order to assist Merck in effectuating the
                  marketing purposes for which this information is obtained, and
                  subject to obtaining a commitment from any entity with whom
                  the information is shared that it will likewise hold the
                  information in confidence and not use it for any other
                  purpose.

             (c)  With respect to the particular items of data noted as
                  exceptions on Schedule 2.3.2, Merck may verbally convey to the
                  entities permitted to receive information under subsection (b)
                  above Merck's summary conclusions drawn from the information
                  contained in the reports provided by Medco, but may not convey
                  the detailed content of the reports.

             (d)  Neither the reports themselves nor Merck's conclusions from
                  the content of those reports may be shared with any pharmacy
                  benefit manager, any

                                      -5-

<PAGE>

                  health care plan that functions as a pharmacy benefit manager,
                  or any entity that offers hardware, software or content to
                  physicians in the POC market.

                                   ARTICLE VII

                        RELATIONSHIP BETWEEN THE PARTIES

         7.1 The relationship between the Parties established under this
Agreement is that of independent contractors and neither Party is an employee,
agent, partner, or joint venture of or with the other.

                                  ARTICLE VIII

                              INTELLECTUAL PROPERTY

         8.1 Merck shall retain all right, title and interest in the materials
that it provides to Medco for use in, on, or in connection with the POC
Channels. However, Merck grants to Medco a perpetual, non-exclusive and
non-royalty-bearing license to use those suggestions and materials in the design
and content of the POC Channels, subject to Article VI.

         8.2 Medco shall retain all right, title and interest in the compilation
of data and reports to be provided to Merck under this Agreement, and in the
data, analyses, and methodologies used to produce the POC Deliverables. However,
Medco grants to Merck a perpetual, non-exclusive and non-royalty bearing license
to use those data, reports, and analyses, subject to Article VI of this
Agreement.

         8.3 As between the Parties, Medco shall retain all right, title and
interest in the content of the POC Channels, except to the extent that Merck
provides such content to Medco.

                                   ARTICLE IX

                                 PATIENT PRIVACY

         9.1 Medco represents and warrants that it will perform all of its
duties under this Agreement in compliance with all applicable federal, state,
local and foreign laws and regulations and licensing requirements, including but
not limited to those related to patient notification, authorization and consent,
privacy of medical records and medical information. By way of example, Medco is
required under the Standards adopted pursuant to the Health Insurance
Portability and Accountability Act of 1996, either directly as a covered entity
or in its role as a business associate of its health plan clients, to assure
that protected health information (all as defined in such Standards) is used or
disclosed only in accordance with such Standards.

                                      -6-

<PAGE>

                                    ARTICLE X

                         REPRESENTATIONS AND WARRANTIES

         10.1 Intellectual Property. Medco represents and warrants that it has
the right to use the POC Channels and to provide the POC Deliverables. Medco's
use of the POC Channels and provision of the POC Deliverables shall not infringe
the Intellectual Property rights of any third party.

         10.2 If at any time during the Term of this Agreement, Medco concludes
that it cannot perform one or more obligations under this Agreement because of
legal or regulatory restrictions imposed upon it, Medco shall promptly notify
Merck, explain why it believes it cannot legally perform the obligation, and
provide Merck with an estimate of the impact of the restriction on its
performance of this Agreement as a whole. Nothing in this Agreement is intended
to allow Medco to create by contract an impediment to performance of this
Agreement that differs from any restriction to which Medco is subject as to
either drug manufacturers generally or any broader category of third-parties.

                                   ARTICLE XI

                                 INDEMNIFICATION

         11.1 Indemnification. Medco shall indemnify and hold harmless the Merck
Indemnitees (as defined in the Indemnification Agreement) in respect of all
Liabilities (as defined in the Indemnification Agreement) related to, arising
from, asserted against or associated with Medco's providing services hereunder.
Such indemnification obligation shall be a Medco Liability for purposes of the
Indemnification Agreement, and the provisions of Article I thereof with respect
to indemnification shall govern with respect thereto.

         11.2 Additional Indemnification. In addition to, and not in limitation
of, the indemnification provided under Section 11.1, Medco shall indemnify and
hold harmless the Merck Indemnitees from and against any and all loss, damage or
expense, including reasonable attorneys' fees, that Merck may sustain or incur
as a result of any claim, suit or proceeding arising out of or in connection
with: (1) any actual or alleged negligent or willful act or omission of Medco,
or any of its employees, agents or subcontractors; (2) any actual or alleged
violation by Medco, or any of its employees, agents or subcontractors of any
law, statute, ordinance or regulation; (3) any failure to obtain necessary
consents, authorizations, approvals or releases for use of the POC Deliverables
hereunder and any violation or alleged violation of any third party or
individual's privacy right by the POC Deliverables provided to Merck under this
Agreement; (4) any infringement or alleged infringement by the POC Deliverables
provided to Merck under this Agreement upon any Intellectual Property rights of
any third party; or (5) any failure to perform any obligation under this
Agreement. Such indemnification obligation shall be a Medco Liability for
purposes of the Indemnification Agreement, and the provisions of Article I
thereof with respect to indemnification shall govern with respect thereto.

                                      -7-

<PAGE>

                                   ARTICLE XII

                               DISPUTE RESOLUTION

         12.1 Any dispute, controversy or claim arising between the Parties
relating to the validity, interpretation or performance of this Agreement shall
be resolved in accordance with the provisions of Article III of the
Indemnification Agreement.

         12.2 Injunctive Relief. Notwithstanding the provisions of Section 12.1,
Medco acknowledges that any violation of Article(s) VI and/or VIII of this
Agreement will cause Merck immediate and irreparable harm that monetary damages
cannot adequately remedy. The parties agree that, upon any actual or impending
violation of Article(s) VI and/or VIII of this Agreement, in addition to any
money damages or other legal remedy that Merck may have, Merck shall also be
entitled to equitable relief, including injunctive relief and specific
performance (and Medco shall not plead in defense thereto that there would be an
adequate remedy at law), without bond or proof of damages. Such equitable relief
may be sought in an arbitration proceeding pursuant to Section 3.1(c) of the
Indemnification Agreement (without first complying with the negotiation
provisions of Section 3.1(a) thereof) or in a court, subject to Section 13.2. In
the event of litigation relating to this Agreement, if a court of competent
jurisdiction determines that Medco has breached Article(s) VI and/or VIII of
this Agreement, Medco shall be liable and pay to Merck the reasonable legal fees
and costs incurred in connection with such litigation, including any appeal from
such litigation.

                                  ARTICLE XIII

                                  MISCELLANEOUS

         13.1 Entire Agreement. This Agreement, the schedules, and any other
agreements specifically referred to in this Agreement constitute the entire
agreement between the Parties with respect to the subject matter of this
Agreement and shall supersede all prior or contemporaneous written or oral
agreements or understandings with respect to the same subject matter.

         13.2 Governing Law; Forum. This Agreement shall be construed in
accordance with, and all Disputes hereunder shall be governed by, the procedural
(except to the extent inconsistent with the procedures set forth in Article III
of the Indemnification Agreement) and substantive laws of the State of New York
as to all matters regardless of the laws that might otherwise govern under
principles of conflicts of laws applicable thereto. Under no circumstances may
any party seek or be awarded punitive damages under this Agreement. Any state
court sitting in New York county, New York and/or the United States District
Court for the Southern District of New York shall have exclusive jurisdiction
and venue, and each party hereto hereby submits to such jurisdiction and venue
and irrevocably waives, to the fullest extent permitted by applicable law, any
objection it may now or hereafter have to such jurisdiction or the laying of
such venue over any Disputes between the parties that are permitted to be
brought in a court, or the enforcement of any decision of an arbitrator,
pursuant to Article III of the Indemnification Agreement. Each of the parties
hereby irrevocably waives any right to a jury trial with respect to a Dispute.

                                      -8-

<PAGE>

         13.3 Descriptive Headings. The headings contained in this Agreement,
including its Schedules and table of contents, are for reference purposes only
and shall not affect in any way the meaning or interpretation of this Agreement.
Any capitalized term used in any Schedule but not otherwise defined therein,
shall have the meaning assigned to such term in this Agreement. When a reference
is made in this Agreement to an Article or a Section, such reference shall be to
an Article or Section of this Agreement unless otherwise indicated.

         13.4 Notices. All notices and other communications required or
permitted to be given by either Party pursuant to the terms of this Agreement
shall be in writing to and shall be deemed to have been duly given when
delivered in person, by express or overnight mail delivery by a nationally
recognized courier (delivery charges prepaid), or by registered or certified
mail (postage prepaid, return receipt requested), as follows:

              if to Merck:

                                   Merck & Co., Inc.
                                   351 N. Sumneytown Pike
                                   North Wales, PA 19454-2505
                                   Attention: Miekeleen Koerth,
                                   Vice President, Sales Strategic Planning

              with a copy to:

                                   Merck & Co., Inc.
                                   One Merck Drive
                                   P.O. Box 100
                                   Whitehouse Station, New Jersey 08889
                                   Attention: General Counsel

              if to Medco:

                                   Medco Health Solutions, Inc.
                                   100 Parsons Pond Road
                                   Franklin Lakes, New Jersey  07417
                                   Attention: General Counsel

or to such other address as the Party to whom notice is given may have
previously furnished to the other in writing in the manner set forth above. All
notices and other communication shall be deemed to have been given and received
on the date of actual delivery.

         13.5 Binding Effect; Assignment; Third-Party Beneficiaries. Medco may
not, directly or indirectly, in whole or in part, whether by operation of law or
otherwise, assign or transfer this Agreement or its rights or obligations
hereunder, without Merck's prior written consent and, except as otherwise
permitted hereby, any attempted assignment, transfer or delegation without such
prior written consent shall be voidable at the sole option of Merck. Merck may
not, without Medco's prior written consent, assign or transfer this Agreement
other than to an Affiliate or in connection with a merger, consolidation, sale
or transfer of all or substantially all of its pharmaceutical business or assets
or any similar business combination transaction. Without limiting the foregoing,
this Agreement shall be binding upon Merck and the other members of

                                      -9-

<PAGE>

the Merck Group (as defined in the Separation Agreement (as defined in the
Indemnification Agreement)), and Medco and the other members of the Medco Group
(as defined in the Indemnification Agreement), and their respective legal
representatives, successors and permitted assigns, and nothing in this
Agreement, express or implied, is intended to confer upon any other Person any
rights or remedies of any nature whatsoever under or by reason of this
Agreement.

         13.6  Offset. In addition to, and not in limitation of, any other
remedies any member of the Merck Group or any Merck Indemnitee (as defined in
the Indemnification Agreement) may be entitled to under the Separation Agreement
any Ancillary Agreement (as defined in the Separation Agreement) (including this
Agreement) or any Intercompany Agreement (as defined in the Indemnification
Agreement) , any member of the Merck Group or any Merck Indemnitee may satisfy
any amounts owed to such member of the Merck Group or Merck Indemnitee by any
member of the Medco Group by means of an offset against any amounts any member
of the Merck Group may from time to time owe to any member of the Medco Group or
an Medco Indemnitee, whether under the Separation Agreement, any Ancillary
Agreement (including this Agreement), any Intercompany Agreement, any other
agreement or arrangement existing between any member of the Merck Group and any
member of the Medco Group, or otherwise.

         13.7  Severability. If any term or other provision of this Agreement is
determined by a court, administrative agency or arbitrator, by any court or in
any binding arbitration, to be invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this
Agreement will nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being
enforced, the Parties shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the Parties as closely as possible in an
acceptable manner to the end that transactions contemplated hereby are fulfilled
to the fullest extent possible. If the Parties are unable to reach an agreement
on any such modification, the arbitrator selected in accordance with Article III
of the Indemnification Agreement shall have the authority to determine such
modification.

         13.8  Failure or Indulgence not Waiver; Remedies Cumulative. No failure
or delay on the part of either Party hereto in the exercise of any right
hereunder shall impair such right or be construed to be a waiver of, or
acquiescence in, any breach of any representation, warranty or agreement herein,
nor shall any single or partial exercise of any such right preclude the further
exercise thereof or of any other right. All rights and remedies existing under
this Agreement are cumulative to, and not exclusive of, any rights or remedies
otherwise available.

         13.9  Amendment. No change or amendment will be made to this Agreement
except by an instrument in writing signed on behalf of each of the Parties
hereto.

         13.10 Counterparts. This Agreement may be executed in counterparts,
which, taken together, shall be considered to be one and the same instrument.

                                      -10-

<PAGE>

         IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed in duplicate originals by its duly authorized representatives.

MERCK & CO., INC.                        MEDCO HEALTH SOLUTIONS, INC.

By: /s/ David W. Anstice                 By: /s/ Robert J. Blyskal
    -----------------------------            --------------------------
Name:  David W. Anstice                  Name:  Robert J. Blyskal
Title: President                         Title: Executive Vice President
       USHH - The Americas                      Operations and Technology

                                      -11-<PAGE>

                                                                   EXHIBIT 10.11

                        DATA FLOW CONTINUATION AGREEMENT

                                     BETWEEN

                                MERCK & CO., INC.

                                       AND

                          MEDCO HEALTH SOLUTIONS, INC.

<PAGE>

                        DATA FLOW CONTINUATION AGREEMENT

     THIS DATA FLOW CONTINUATION AGREEMENT, dated as of June 28, 2002, is
entered into among Merck & Co., Inc., a New Jersey corporation ("Merck") and
Medco Health Solutions, Inc., a Delaware corporation ("Medco"). Merck and Medco
are referred to collectively as the "Parties."

                                    RECITALS

     A.  Medco currently provides (directly or through a subsidiary) certain
non-patient identifiable and non plan identifiable data to IMS Health
Incorporated ("IMS"), pursuant to an agreement dated January 1, 2000 which
requires Medco to continue to provide data to IMS through December 31, 2002 and
consistent with applicable laws.

     B.  IMS currently provides certain data and information services to Merck
pursuant to an Information Services Agreement between IMS and Merck dated
January 1, 2000, as amended (the "Information Services Agreement"). The
Information Services Agreement requires IMS to continue to provide data and
services through the December 31, 2004 data month.

     C.  Medco is a Data Supplier (as defined in section 6 of the Information
Services Agreement) and allows information that it furnishes to IMS ("Medco
Data") to be included in Data (as defined in the Information Services Agreement)
that IMS in turn furnishes to Merck.

     D.  Merck and Medco are undergoing a change in corporate structure which is
not intended to affect the performance of either of the referenced agreements,
and the Parties wish to preserve the flow of information that currently exists
between them under those agreements.

ACCORDINGLY, the Parties agree as follows:

                                    ARTICLE I

                               DATA TO BE PROVIDED

     1.1 Medco agrees that it will continue to provide information to IMS
consistent with the information it has provided since January 1, 2000, and that
for so long as it remains a Data Supplier to IMS, Medco Data may continue to be
provided to Merck under the terms of the Information Services Agreement and
consistent with the way such Data has been provided by IMS to Merck since
January 1, 2000.

     1.2 In the event that Medco ceases to be a Data Supplier to IMS at any time
prior to December 31, 2004, Medco agrees that it will provide Medco Data to
Merck directly through the data month ending December 31, 2004.

     1.3 Medco agrees that from the date of this Agreement through December 31,
2004, it shall continue to provide to Merck, either directly or through IMS, the
data listed in Schedule 1A, subject to the restrictions contained in that
Schedule.

<PAGE>

                                   ARTICLE II

                          COMPENSATION AND TERMINATION

     2.1 Merck shall pay Medco the fees set forth in Schedule 2A.

     2.2 Merck may terminate this Agreement for any reason or no reason,
effective January 1, 2003 or at any later date, upon at least 90 days prior
written notice to Medco. In the event of termination, the fees payable under
Section 2.1 shall be reduced pro rata for the number of months left in the year
if the services are terminated mid-year.

                                   ARTICLE III

                        RELATIONSHIP BETWEEN THE PARTIES

     3.1 The relationship between the Parties established under this Agreement
is that of independent contractors and neither Party is an employee, agent,
partner, or joint venturer of or with the other.

                                   ARTICLE IV

                                 PATIENT PRIVACY

     4.1 Medco represents and warrants that it will perform all of its duties
under this Agreement in compliance with all applicable federal, state, local and
foreign laws and regulations and licensing requirements, including but not
limited to those related to patient notification, authorization and consent,
privacy of medical records and medical information. By way of example, Medco is
required under the Standards adopted pursuant to the Health Insurance
Portability and Accountability Act of 1996, either directly as a covered entity
or in its role as a business associate of its health plan clients, to assure
that protected health information (all as defined in such Standards) is used or
disclosed only in accordance with such Standards.

                                    ARTICLE V

                         REPRESENTATIONS AND WARRANTIES

     5.1 Intellectual Property. Medco represents and warrants that it has the
right to provide the Medco Data, and that its provision of Medco Data shall not
infringe the intellectual property rights of any third party.

<PAGE>

                                   ARTICLE VI

                                 INDEMNIFICATION

     6.1 Indemnification. Medco shall indemnify and hold harmless the Merck
Indemnitees (as defined in the Indemnification and Insurance Agreement to be
entered into by the Parties (the "Indemnification Agreement")) in respect of all
Liabilities (as defined in the Indemnification Agreement) related to, arising
from, asserted against or associated with Medco's providing data hereunder. Such
indemnification obligation shall be a Medco Liability for purposes of the
Indemnification Agreement, and the provisions of Article I thereof with respect
to indemnification shall govern with respect thereto.

     6.2 Additional Indemnification. In addition to, and not in limitation of,
the indemnification provided under Section 6.1, Medco shall indemnify and hold
harmless the Merck Indemnitees from and against any and all loss, damage or
expense, including reasonable attorneys' fees, that Merck may sustain or incur
as a result of any claim, suit or proceeding arising out of or in connection
with: (1) any actual or alleged negligent or willful act or omission of Medco,
or any of its employees, agents or subcontractors; (2) any actual or alleged
violation by Medco, or any of its employees, agents or subcontractors of any
law, statute, ordinance or regulation; (3) any failure to obtain necessary
consents, authorizations, approvals or releases for use of the Medco Data and
any violation or alleged violation of any third party or individual's privacy
right by the Medco Data provided to Merck under this Agreement; (4) any
infringement or alleged infringement by the Medco Data provided to Merck under
this Agreement upon any intellectual property right of any third party; or (5)
any failure to perform any obligation under this Agreement. Such indemnification
obligation shall be a Medco Liability for purposes of the Indemnification
Agreement, and the provisions of Article I of that agreement with respect to
indemnification shall govern with respect to that liability.

                                   ARTICLE VII

                               DISPUTE RESOLUTION

     7.1 Any dispute, controversy or claim arising between the Parties relating
to the interpretation, validity or performance of this Agreement shall be
resolved in accordance with the provisions of Article III of the Indemnification
Agreement.

<PAGE>

     7.2 Injunctive Relief. Notwithstanding the provisions of Section 7.1, Medco
acknowledges that any violation of Article I of this Agreement will cause Merck
immediate and irreparable harm that monetary damages cannot adequately remedy.
The parties agree that, upon any actual or impending violation of Article I of
this Agreement, in addition to any money damages or other legal remedy that
Merck may have, Merck shall also be entitled to equitable relief, including
injunctive relief and specific performance (and Medco shall not plead in defense
thereto that there would be an adequate remedy at law), without bond or proof of
damages. Such equitable relief may be sought in an arbitration proceeding
pursuant to Section 3.1(c) of the Indemnification Agreement (without first
complying with the negotiation provisions of Section 3.1(a) thereof) or in a
court, subject to Section 8.2. In the event of litigation relating to this
Agreement, if a court of competent jurisdiction determines that Medco has
breached Article I of this Agreement, Medco shall be liable and pay to Merck the
reasonable legal fees and costs incurred in connection with such litigation,
including any appeal from such litigation.

                                   ARTCLE VIII

                                  MISCELLANEOUS

     8.1 Entire Agreement. This Agreement and any other agreements specifically
referred to in this Agreement constitute the entire agreement between the
Parties with respect to the subject matter of this Agreement and shall supersede
all prior or contemporaneous written or oral agreements or understandings with
respect to the same subject matter.

     8.2 Governing Law; Forum. This Agreement shall be construed in accordance
with, and all Disputes hereunder shall be governed by, the procedural (except to
the extent inconsistent with the procedures set forth in Article III of the
Indemnification Agreement) and substantive laws of the State of New York as to
all matters regardless of the laws that might otherwise govern under principles
of conflicts of laws applicable thereto. Under no circumstances may any party
seek or be awarded punitive damages under this Agreement. Any state court
sitting in New York county, New York and/or the United States District Court for
the Southern District of New York shall have exclusive jurisdiction and venue,
and each party hereto hereby submits to such jurisdiction and venue and
irrevocably waives, to the fullest extent permitted by applicable law, any
objection it may now or hereafter have to such jurisdiction or the laying of
such venue over any Disputes between the parties that are permitted to be
brought in a court, or the enforcement of any decision of an arbitrator,
pursuant to Article III of the Indemnification Agreement. Each of the parties
hereby irrevocably waives any right to a jury trial with respect to a Dispute.

     8.3 Interpretation. The headings contained in this Agreement, including its
Schedules and table of contents, are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement. Any
capitalized term used in any Schedule but not otherwise defined therein, shall
have the meaning assigned to such term in this Agreement. When a reference is
made in this Agreement to an Article or a Section, such reference shall be to an
Article or Section of this Agreement unless otherwise indicated.

<PAGE>

     8.4 Notices. All notices and other communications required or permitted to
be given by either Party pursuant to the terms of this Agreement shall be in
writing to and shall be deemed to have been duly given when delivered in person,
by express or overnight mail delivery by a nationally recognized courier
(delivery charges prepaid), or by registered or certified mail (postage prepaid,
return receipt requested), as follows:

         if to Merck:

                             Merck & Co., Inc.
                             Sumneytown Pike
                             P.O. Box 4
                             West Point, PA 19486
                             Attention: Hal Petrimoulx,
                             Executive Director, Information Management
                             and Development

         With a copy to:

                             Merck & Co., Inc.
                             One Merck Drive
                             P.O. Box 100
                             Whitehouse Station, New Jersey 08889
                             Attention: General Counsel

         if to Medco:

                             Medco Health Solutions, Inc.
                             100 Parsons Pond Road
                             Franklin Lakes, New Jersey 07417
                             Attention: General Counsel

or to such other address as the Party to whom notice is given may have
previously furnished to the other in writing in the manner set forth above. All
notices and other communication shall be deemed to have been given and received
on the date of actual delivery.

     8.5 Binding Effect; Assignment; Third-Party Beneficiaries. Medco may not,
directly or indirectly, in whole or in part, whether by operation of law or
otherwise, assign or transfer this Agreement or its rights or obligations
hereunder, without Merck's prior written consent and, except as otherwise
permitted hereby, any attempted assignment, transfer or delegation without such
prior written consent shall be voidable at the sole option of Merck. Nothing in
this Agreement shall restrict any transfer of this Agreement by Merck, whether
by operation of law or otherwise. Without limiting the foregoing, this Agreement
shall be binding upon Merck and the other members of the Merck Group and Medco
and the other members of the Medco Group and their respective legal
representatives, successors and permitted assigns, and nothing in this
Agreement, express or implied, is intended to confer upon any other Person any
rights or remedies of any nature whatsoever under or by reason of this
Agreement.

<PAGE>

     8.6  Offset. In addition to, and not in limitation of, any other remedies
any member of the Merck Group or any Merck Indemnitee (as defined in the
Indemnification Agreement) may be entitled to under the Separation Agreement (as
defined in the Indemnification Agreement), any Ancillary Agreement (as defined
in the Separation Agreement) (including this Agreement) or any Intercompany
Agreement (as defined in the Indemnification Agreement) , any member of the
Merck Group or any Merck Indemnitee may satisfy any amounts owed to such member
of the Merck Group or Merck Indemnitee by any member of the Medco Group by means
of an offset against any amounts any member of the Merck Group may from time to
time owe to any member of the Medco Group or an Medco Indemnitee, whether under
the Separation Agreement, any Ancillary Agreement (including this Agreement),
any Intercompany Agreement, any other agreement or arrangement existing between
any member of the Merck Group and any member of the Medco Group, or otherwise.

     8.7  Severability. If any term or other provision of this Agreement is
determined by a court, administrative agency or arbitrator, by any court or in
any binding arbitration, to be invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this
Agreement will nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being
enforced, the Parties shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the Parties as closely as possible in an
acceptable manner to the end that transactions contemplated hereby are fulfilled
to the fullest extent possible. If the Parties are unable to reach an agreement
on any such modification, the arbitrator selected in accordance with Article III
of the Indemnification Agreement shall have the authority to determine such
modification.

     8.8  Failure or Indulgence Not Waiver. No failure or delay on the part of
either Party hereto in the exercise of any right hereunder shall impair such
right or be construed to be a waiver of, or acquiescence in, any breach of any
representation, warranty or agreement herein, nor shall any single or partial
exercise of any such right preclude other or further exercise thereof or of any
other right.

     8.9  Amendment. No change or amendment will be made to this Agreement
except by an instrument in writing signed on behalf of each of the Parties
hereto.

     8.10 Counterparts. This Agreement and the other documents referred to
herein may be executed in counterparts, each of which shall be deemed an
original but all of which, taken together, shall constitute one and the same
instrument.

<PAGE>

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed
in duplicate originals by its duly authorized representatives.

MERCK & CO., INC.                            MEDCO HEALTH SOLUTIONS, INC.

By:  /s/ David W. Anstice                    By:  /s/ Robert J. Blyskal
    ------------------------------               ------------------------------
Name:  David W. Anstice                      Name:  Robert J. Blyskal
Title: President                             Title: Executive Vice President
       USHH-The Americas                            Operations and Technology

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]